News Release

View printer-friendly version
<< Back

POZEN Announces Key Leadership Additions


Three New Executives, Each Bring Decades of Experience Working at High Growth Pharmaceutical Companies

New Executives Will Also Serve on Leadership Team of Aralez Pharmaceuticals, Following Completion of Merger with Tribute

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Jun. 22, 2015-- POZEN Inc. (“POZEN”) (NASDAQ:POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced appointments to its Executive Leadership Team led by newly appointed Chief Executive Officer, Adrian Adams.

The new appointments, are as follows:

  • Mark A. Glickmanhas been named Chief Commercial Officer of POZEN, a newly created position effective immediately, with the intention of becoming Chief Commercial Officer of Aralez Pharmaceuticals upon the completion of the pending merger between POZEN and Tribute;
  • Eric L. Trachtenberghas been named Deputy General Counsel of POZEN, effective immediately, with the intention of becoming General Counsel of Aralez Pharmaceuticals upon the completion of the pending merger between POZEN and Tribute; and
  • Jennifer L. Armstronghas been named Executive Vice President, Human Resources and Administration of POZEN, effective immediately, with the intention of becoming EVP Human Resources and Administration of Aralez Pharmaceuticals upon completion of the pending merger between POZEN and Tribute.

“This is an exciting time for POZEN as we work to combine with Tribute and create Aralez Pharmaceuticals, a premier specialty pharmaceutical company with enhanced offerings and a diversified product portfolio that we believe will provide significant benefits for all of our stakeholders. With the enhancements to the leadership team announced today, I’m confident we will execute at an even faster pace as we head into this next phase of growth and success,” said Adrian Adams, Chief Executive Officer of POZEN. “I look forward to working in close partnership with Mark, Eric and Jennifer as we work together with all our valued employees to build an even stronger company.”

About Mark A. Glickman

Mr. Glickman has over 20 years of experience in pharmaceutical sales and operations, with expertise in a variety of fields including sales turnarounds, global product introductions and organizational expansions. Mr. Glickman most recently served as Executive Vice President of Sales and Marketing for Auxilium Pharmaceuticals. Prior to that, he served as Vice President in the medical device division at Otsuka America Pharmaceutical, Inc. At Otsuka, he helped to reinvigorate the company’s sales and increase its business by 50% over two years, while also spearheading quality improvement initiatives and playing a critical role in new regulatory filings. Prior to Otsuka, Mr. Glickman served as Senior Vice President of Sales and Marketing at Oscient Pharmaceuticals Corp., during which time he completed a successful turnaround of the company’s commercial strategy, driving a significant increase in sales. Before joining Oscient, Mr. Glickman served as Vice President of Sales at Bayer Healthcare’s Diabetes Care Division. From 2001 to 2007 he played a major role in helping to build the commercial organization at Kos Pharmaceuticals and held various positions including Director of Marketing, Regional Sales Director and Vice President of Sales. Mr. Glickman started his pharmaceutical career at Bristol-Myers Squibb where he was responsible for the marketing of cardiovascular products, including the blockbuster Plavix. Mr. Glickman holds a Master of Business Administration degree from New York University.

About Eric L. Trachtenberg

Mr. Trachtenberg has over 16 years of experience practicing law, including over ten years in the pharmaceutical industry. Mr. Trachtenberg most recently served as Deputy General Counsel at Auxilium Pharmaceuticals, Inc., from 2012 through its acquisition by Endo Pharmaceuticals in February 2015. Prior to Auxilium, he was Vice President, General Counsel and Corporate Secretary of Enobia Pharma, Inc. and managed all legal aspects of Enobia’s sale to Alexion Pharmaceuticals. Prior to that, Mr. Trachtenberg served as Vice President and Associate General Counsel of Sepracor Inc. and remained in that position with Sunovion Pharmaceuticals Inc. following the acquisition of Sepracor by Dainippon Sumitomo Pharma. Mr. Trachtenberg also held a Senior Counsel position at Kos Pharmaceuticals, Inc. before its acquisition by Abbott. Mr. Trachtenberg began his career as an Associate at Blank Rome LLP. He holds a Bachelor of Science degree in Management from Tulane University and a Juris Doctorate and Master of Business Administration degree from Temple University.

About Jennifer L. Armstrong

Ms. Armstrong has over 15 years of experience in the Human Resources field, primarily in the biotech industry. Ms. Armstrong most recently served as Senior Vice President of Human Resources at Auxilium Pharmaceuticals, Inc. Prior to that, she served at Senior Vice President of Human Resources and Corporate Communications at Genaera Corporation. During her decade long tenure at Genaera, Ms. Armstrong was responsible for all facets of Human Resources, including working directly with the Compensation Committee on executive and equity compensation strategies. She also was responsible for investor and public relations while overseeing the IT and facilities functions. Ms. Armstrong holds a Masters degree in Arts Administration and a Bachelors degree in Corporate Communications, both from Drexel University.


POZEN Inc. is a specialty pharmaceutical company that to date has historically focused on developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

POZEN’s common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit

Cautionary Language Concerning Forward-Looking Statements

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Aralez Pharmaceuticals, POZEN and Tribute and the timing and benefits thereof, the anticipated equity and debt financings and the closings thereof, the combined company's strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, anticipated product portfolio, development programs and management structure, the proposed listing on the NASDAQ and TSX and other statements that are not historical facts. These forward-looking statements are based on POZEN's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the parties ability to complete the combination and financings on the proposed terms and schedule; the parties ability to close the capital investment on the proposed terms and schedule; the combined company meeting the listing on the NASDAQ and TSX; risk that Aralez Pharmaceuticals may be taxed as a U.S. resident corporation; risks associated with business combination transactions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed transaction; disruption from the proposed transaction, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; the calculations of, and factors that may impact the calculations of, the acquisition price in connection with the proposed merger and the allocation of such acquisition price to the net assets acquired in accordance with applicable accounting rules and methodologies; and the possibility that if the combined company does not achieve the perceived benefits of the proposed transaction as rapidly or to the extent anticipated by financial analysts or investors, the market price of the combined company's shares could decline, as well as other risks related to POZEN's business, including POZEN's inability to build, acquire or contract with a sales force of sufficient scale for the commercialization of YOSPRALA™ in a timely and cost-effective manner, the parties’ failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates (including YOSPRALA™), including as a result of the need to conduct additional studies or due to issues with third-party manufacturers, or the failure to obtain such approval of POZEN’s product candidates for all expected indications, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of its product candidates; the inability to maintain or enter into, and the risks resulting from POZEN’s dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including its dependence on AstraZeneca and Horizon for the sales and marketing of VIMOVO®, POZEN’s dependence on Patheon for the manufacture of YOSPRALA™ 81/40 and YOSPRALA™ 325/40 ; the ability of the parties to protect its intellectual property and defend its patents; regulatory obligations and oversight; and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in POZEN'sSEC filings and reports, including in its Annual Report on Form 10-K for the year ended December 31, 2014 and Form 10-Q for the quarter ended March 31, 2015 and in Tribute’s SEC filings and report, including in its Annual Report on Form 10-K for the year ended December 31, 2014 and Form 10-Q for the quarter ended March 31, 2015. POZEN undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or changes in their expectations.

Source: POZEN Inc.

Bill Hodges, 919-913-1030
Chief Financial Officer
Stephanie Bonestell, 919-913-1030
Manager, Investor Relations & Public Relations

Copyright West LLC. Minimum 15 minutes delayed.